ArticleCost effectiveness and resource allocation : C/E2024

Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

Yusi Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.